Evidence map›Paper›PMID 27347172›Full record

ArticleOncology letters2016

The impact of high co-expression of Sp1 and HIF1α on prognosis of patients with hepatocellular cancer.

Liang Liu, Ping Ji, Ning Qu, Wei-Lin Pu, Dao-Wen Jiang, Wei-Yan Liu, Ya-Qi Li, Rong-Liang Shi

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Specificity Proteins (Sp) and Cancer.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Liang LiuDepartment of Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, P.R. China.
Ping JiShanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai 201508, P.R. China.
Ning QuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, P.R. China.
Wei-Lin PuMinistry of Education Key Laboratory of Contemporary Anthropology and State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200433, P.R. China.
Dao-Wen JiangDepartment of General Surgery, Minhang Hospital, Fudan University, Shanghai 201199, P.R. China.
Wei-Yan LiuDepartment of General Surgery, Minhang Hospital, Fudan University, Shanghai 201199, P.R. China.
Ya-Qi LiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, P.R. China.
Rong-Liang ShiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, P.R. China; Department of General Surgery, Minhang Hospital, Fudan University, Shanghai 201199, P.R. China.
Fudan University Shanghai Cancer Center · CNFudan University · CNMinhang District Central Hospital · CNShanghai Public Health Clinical Center · CNState Key Laboratory of Genetic Engineering

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription factor specificity protein 1 (Sp1) and hypoxia-inducible factor 1α (HIF1α) serve vital roles in tumor growth and metastasis. The present study aimed to evaluate the impact of co-expression of Sp1 and HIF1α on the prognosis of patients with hepatocellular cancer (HCC) using The Cancer Genome Atlas (TCGA) database and to validate the association between the expression levels of Sp1/HIF1α in HCC specimens and patient survival using immunohistochemical analysis. A total of 214 eligible patients with HCC from TCGA database were collected for the study. The expression profile of Sp1 and HIF1α were obtained from the TCGA RNAseq database. Clinicopathological characteristics, including age, height, weight, gender, race, ethnicity, family cancer history, serum α-fetoprotein (AFP), surgical procedures and TNM stage were collected. The Cox proportional hazards regression model and Kaplan-Meier curves were used to assess the relative factors. Receiver operating characteristic (ROC) curves for cancer-specific survival (CSS) prediction were plotted to compare the prediction ability of expression of Sp1 and HIF1α and their co-expression. The location and expression of Sp1 and HIF1α in the HCC tissues were detected by immunohistochemistry (IHC) to verify the association between these two genes and CSS. The results demonstrated that the expressions of Sp1 and HIF1α were significantly increased in the succumbed group (P=0.001), compared with the surviving group. The CSS rates were 60.1% at 3 years (1,067 days), 35.8% at 5 years (1,823 days) and 9.5% at 10 years (3,528 days). Multivariate Cox regression analysis demonstrated that only the high expression levels of Sp1 and HIF1α (≥2×10

Indexed as

hepatocellular cancerHIF1αprognosisSp1The Cancer Genome Atlas

Identifiers

PMID27347172
PMCPMC4906840
OpenAlexW2400760457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.